Abstract：Lysinuric protein intolerance (LPI) is an autosomal recessive disorder caused by SLC7A7 gene mutation and often involves severe lesions in multiple systems. Lung involvement is frequently seen in children with LPI and such children tend to have a poor prognosis. This article summarizes the clinical manifestations and gene mutation characteristics of three children diagnosed with LPI by SLC7A7 gene analysis. All three children had the manifestations of aversion to protein-rich food after weaning, delayed development, anemia, hepatosplenomegaly, and osteoporosis, as well as an increase in orotic acid in urine. In addition, interstitial pneumonia and diffuse pulmonary interstitial lesions were observed in two children. SLC7A7 gene detection showed three pathogenic mutations in these children, namely c.1387delG(p.V463CfsX56), c.1215G > A(p.W405X) and homozygous c.625+1G > A. After a definite diagnosis was made, all three children were given a low-protein diet and oral administration of citrulline[100 mg/(kg·d)], iron protein succinylate[4 mg/(kg·d)], calcium and zinc gluconates oral solution (10 mL/day) and vitamin D (400 IU/day). In addition, patient 3 was given prednisone acetate (5 mg/day). The children had varying degrees of improvement in symptoms and signs. It is hard to distinguish LPI from urea cycle disorder due to the features of amino acid and organic acid metabolism in LPI, and SLC7A7 gene analysis is the basis for a definite diagnosis of LPI.
CUI Dong,HU Yu-Hui,TANG Gen et al. Clinical features of children with lysinuric protein intolerance and SLC7A7 gene mutation: an analysis of 3 cases[J]. CJCP, 2019, 21(4): 375-380.
Perheentupa J, Visakorpi JK. Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism[J]. Lancet, 1965, 2(7417):813-816.
[2]
Sebastio G, Sperandeo MP, Andria G. Lysinuric protein intolerance:reviewing concepts on a multisystem disease[J]. Am J Med Genet C Semin Med Genet, 2011, 157C(1):54-62.
[3]
Sperandeo MP, Bassi MT, Riboni M, et al. Structure of the SLC7A7 gene and mutational analysis of patients affected by lysinuric protein intolerance[J]. Am J Hum Genet, 2000, 66(1):92-99.
[4]
Sperandeo MP, Andria G, Sebastio G. Lysinuric protein intolerance:update and extended mutation analysis of the SLC7A7 gene[J]. Hum Mutat, 2008, 29(1):14-21.
[5]
Mauhin W, Habarou F, Gobin S, et al. Update on lysinuric protein intolerance, a multi-faceted disease retrospective cohort analysis from birth to adulthood[J]. Orphanet J Rare Dis, 2017, 12(1):1-12.
[6]
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[7]
Torrents D, Mykkänen J, Pineda M, et al. Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene[J]. Nat Genet, 1999, 21(3):293-296.
[8]
Shoji Y, Noguchi A, Shoji Y, et al. Five novel SLC7A7 variants and y+L gene-expression pattern in cultured lymphoblasts from Japanese patients with lysinuric protein intolerance[J]. Hum Mutat, 2002, 20(5):375-381.
[9]
Noguchi A, Nakamura K, Murayama K, et al. Clinical and genetic features of lysinuric protein intolerance in Japan[J]. Pediatr Int, 2016, 58(10):979-983.
[10]
DiRocco M, Garibotto G, Rossi GA, et al. Role of haematological, pulmonary and renal complications in the longterm prognosis of patients with lysinuric protein intolerance[J]. Eur J Pediatr, 1993, 152(5):437-440.
[11]
Parenti G, Sebastio G, Strisciuglio P, et al. Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course[J]. J Pediatr, 1995, 126(2):246-251.
[12]
Parsons H, Snyder F, Bowen T, et al. Immune complex disease consistent with systemic lupus erythematosus in a patient with lysinuric protein intolerance[J]. J Inherit Metab Dis, 1996, 19(5):627-634.
[13]
Gürsel T, Koçak U, Tümer L, et al. Bone marrow hemophagocytosis and immunological abnormalities in a patient with lysinuric protein intolerance[J]. Acta Haematol, 1997, 98(3):160-162.
[14]
Santamaria F, Parenti G, Guidi G, et al. Early detection of lung involvement in lysinuric protein intolerance:role of highresolution computed tomography and radioisotopic methods[J]. Am J Respir Crit Care Med, 1996, 153(2):731-735.
[15]
Parto K, Svedström E, Majurin ML, et al. Pulmonary manifestations in lysinuric protein intolerance[J]. Chest, 1993, 104(4):1176-1182.
[16]
Valimahamed-Mitha S, Berteloot L, Ducoin H, et al. Lung involvement in children with lysinuric protein intolerance[J]. J Inherit Metab Dis, 2015, 38(2):257-263.
[17]
Zhang G, Cao L. New mutations in the SLC7A7 gene of two chinese sisters with lysinuric protein intolerance[J]. Pediatr Pulmonol, 2017, 52(11):E94-E96.
[18]
Rotoli BM, Barilli A, Visigalli R, et al. Downregulation of SLC7A7 triggers an inflammatory phenotype in human macrophages and airway epithelial cells[J]. Front Immunol, 2018, 9:508.
[19]
Douda DN, Farmakovski N, Dell S, et al. SP-D counteracts GM-CSF-mediated increase of granuloma formation by alveolar macrophages in lysinuric protein intolerance[J]. Orphanet J Rare Dis, 2009, 4:29.
[20]
Santamaria F, Brancaccio G, Parenti G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance[J]. J Pediatr, 2004, 145(2):268-272.
